EUCTR2010-022170-14-DK进行中（未招募）1 期
Open-label, ascending-dose, Phase II study to determine the minimum effective dose of APD421 (intravenous amisulpride) in the prevention of cisplatin-induced nausea and vomiting - Phase II proof-of-concept study of APD421
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patients = 18 years of age.
- •2.Ability and willingness to give written informed consent.
- •3.Patients scheduled to receive, on day 1 of their chemotherapy, a first cisplatin chemotherapy infusion at a dose of 50 mg/m2 or greater.
- •4.Karnofsky performance score = 60%.
- •5.Adequate cardiac, hepatic and renal function
- •QTc interval < 500 ms
- •Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) < 5 x upper limit normal (ULN)
- •Bilirubin < 3 x ULN
- •Creatinine < 2 x ULN.
- •6.Adequate haematological function
- •Haemoglobin = 9 g/dL
- •White blood count = 3.0 x 109/L
- •Platelet count = 100 x 109/L
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients scheduled to receive, prior to or in the 24 hours after cisplatin, any chemotherapeutic agent with a high or moderate emetic risk according to published criteria.
- •2.Patients scheduled to receive paclitaxel or docetaxel.
- •3.Patients undergoing abdominal or pelvic irradiation within 48 hours prior to screening or scheduled to receive abdominal or pelvic irradiation between screening and 24 hours after cisplatin administration.
- •4.Patients receiving amisulpride for any indication within the last 2 weeks.
- •5.Patients who are allergic to amisulpride or any of the excipients of APD421.
- •6.Patients with a pre-existing vestibular disorder.
- •7.Patients being treated with regular anti-emetic therapy including corticosteroids.
- •8.Patients receiving inhaled corticosteroids, unless started more than one month prior to the expected date of study entry.
- •9.Patients being treated with medications which could induce torsades de pointes, including Class Ia antiarrhythmic agents such as quinidine, disopyramide, procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and other medications such as bepridil, cisapride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin.
- •10.Patients being treated with levodopa.
- •11.Patients receiving benzodiazepines, unless on a stable dose for at least one month prior to the expected date of study entry.
- •12.Patients with pre-existing nausea or vomiting in the 24 hours before receiving cisplatin chemotherapy, e.g. anticipatory emesis.
- •13.Patients who are pregnant or breast feeding.
- •14.Patients with a history of alcohol abuse.
- •15.Patients with pre-existing, clinically significant cardiac arrhythmia.
- •16.Any other concurrent disease or illness that, in the opinion of the investigator makes the patient unsuitable for the study.
- •17.Patients who have participated in another study within the previous 28 days.
研究者
相似试验
进行中（未招募）
不适用
Open-label, ascending-dose, Phase II study to determine the minimum effective dose of APD421 (intravenous amisulpride) in the prevention of cisplatin-induced nausea and vomiting - Phase II proof-of-concept study of APD421EUCTR2010-022170-14-GBAcacia Pharma Ltd40
进行中（未招募）
1 期
Dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta-thalassemia (ß-thalassemia)Subjects with red blood cell (RBC) transfusion dependent ß-thalassemia major and ß thalassemia intermedia, as well as non-transfusion dependent ß-thalassemia intermedia will take part in this study.MedDRA version: 20.1Level: LLTClassification code 10062923Term: Thalassemia intermediaSystem Organ Class: 100000004850MedDRA version: 20.1Level: LLTClassification code 10054661Term: Thalassemia majorSystem Organ Class: 100000004850MedDRA version: 20.1Level: LLTClassification code 10054660Term: Thalassemia betaSystem Organ Class: 100000004850EUCTR2011-005659-15-GRCelgene Corporation85
进行中（未招募）
1 期
Dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta-thalassemia (ß-thalassemia)EUCTR2011-005659-15-GBCelgene Corporation85
进行中（未招募）
1 期
Dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta-thalassemia(ß)-thalassemiaSubject with red blood cell (RBC) transfusion dependent beta (ß)-thalassemia major and beta(ß)-thalassemia intermedia as well as non-transfusion dependent beta(ß)-thalassemia intermedia will take part in this studyMedDRA version: 14.1Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10062923Term: Thalassemia intermediaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10054661Term: Thalassemia majorSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10054660Term: Thalassemia betaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-005659-15-ITCELGENE CORPORATIO46
进行中（未招募）
1 期
A clinical trial to assess the safety and effects of a novel medicine intended for the treatment of patients with liver disease due to Alpha-1 Antitrypsin Deficiency (AATD)EUCTR2016-000917-59-IEArrowhead Pharmaceuticals, Inc12